Different PSA assays lead to detection of prostate cancers with identical histological features

European Urology

Volumn 42, Issue 2, 2002, Pages 154-158

  Yurdakul, G ^a   Bangma, C H ^a   Blijenberg, B G ^a   Van Zelst, B D ^a   Wildhagen, M F ^a   Van der Kwast, Th H ^a   Schroder F H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prostate cancer; PSA assays; Tumour characteristics

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; RELIABILITY; SIMULATION; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME; ANALYTICAL EQUIPMENT; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROSTATE TUMOR; REGRESSION ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; COMPARATIVE STUDY; HUMAN; MALE; MIDDLE AGE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; HUMANS; MIDDLE AGED;

EID: 0036668365     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00278-6     Document Type: Article

References (20)

1. Prostate specific-antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
2. Defining the ideal tumor marker for prostate cancer
3. Clinical behaviour of prostate-specific antigen and prostatic acid phosphatase: A comparative study
4. Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: An unusual clinical scenario
5. Clinical and US findings in prostate cancers: Patients with normal prostate-specific antigen levels
6. Variation in measurement of prostate-specific antigen: Importance of method and lot variability
7. Prostate-specific antigen: Problems in analysis
8. Measurement of prostate-specific antigen in serum using four different immunoassays
9. Comparability of the Tandem R and Imx assays for the measurement of serum prostate-specific antigen
10. Free and total prostate-specific antigen in a screened population
11. Evaluation of PSA, DRE and TRUS in population based screening for prostate cancer: Suggestions to improve the efficiency of early detection
12. Biological variation of prostate-specific antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well defined cohort of 24 patients
13. A new biomedicalprocedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry (Part I)
14. Discordant performance of assays for free and total PSA in relation to the early detection of prostate cancer
15. The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy
16. Screening for prostate carcinoma with prostate-specific antigen
17. Changing role of 3 screening modalities in the European Randomized Study for Prostate Cancer (Rotterdam)
18. Tumor volume and prostate-specific antigen: Implications for early detection and defining of a window of curability
19. Localised prostate cancer: Relationship of tumor volume to clinical significance for treatment of prostate cancer
20. Prostate cancer detection at low PSA